Biogen rises after Novo Nordisk's drug fails to meet main goal in Alzheimer's trials

Eisai

24/11/2025 11:54

** Shares of Biogen BIIB.O rise 5.1% to $184.25 premarket

** Novo Nordisk NOVOb.CO says its diabetes drug Rybelsus failed to meet its main goal in late-stage trials testing whether the medicine can slow cognitive decline in Alzheimer's patients

** The study was keenly watched as an indication of whether blockbuster GLP-1 drugs - a class being used by millions for diabetes and weight loss - can slow progress of Alzheimer's

** Biogen and partner Eisai's 4523.T Leqembi and rival Eli Lilly's LLY.N Kisunla are the only approved treatments for Alzheimer's in the U.S.

** The Danish drugmaker's Rybelsus and blockbuster drugs Ozempic and Wegovy are based on the same active ingredient, semaglutide

** Up to last close, Biogen has gained ~15% YTD

 (Reporting by Mariam Sunny in Bengaluru)

 ((Mariam.ESunny@thomsonreuters.com;))